神经内分泌前列腺癌治疗的现状和未来方向

IF 9.6 1区医学 Q1 ONCOLOGY

Cancer treatment reviews Pub Date : 2025-04-09 DOI:10.1016/j.ctrv.2025.102941

Gokce Belge Bilgin , Fabrice Lucien-Matteoni , Aadel A. Chaudhuri , Jacob J. Orme , Daniel S. Childs , Miguel Muniz , Gary G. Li , Pradeep S. Chauhan , SeungBaek Lee , Sounak Gupta , Matthew P. Thorpe , Derek R. Johnson , Geoffrey B. Johnson , Ayse Tuba Kendi , Oliver Sartor

{"title":"神经内分泌前列腺癌治疗的现状和未来方向","authors":"Gokce Belge Bilgin , Fabrice Lucien-Matteoni , Aadel A. Chaudhuri , Jacob J. Orme , Daniel S. Childs , Miguel Muniz , Gary G. Li , Pradeep S. Chauhan , SeungBaek Lee , Sounak Gupta , Matthew P. Thorpe , Derek R. Johnson , Geoffrey B. Johnson , Ayse Tuba Kendi , Oliver Sartor","doi":"10.1016/j.ctrv.2025.102941","DOIUrl":null,"url":null,"abstract":"<div><div>Neuroendocrine prostate cancer (NEPC) is rare at the time of initial diagnosis but much more common in patients treated with the combination of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) such as abiraterone and enzalutamide. NEPC is typically characterized by the loss of prostate-specific membrane antigen (PSMA) expression while exhibiting variable neuroendocrine markers. Recent advancements in nuclear medicine have provided a promising avenue for the development of molecular imaging techniques and targeted therapies tailored to NEPC. This review examines the current and future role of theranostics in the diagnosis and management of NEPC and explores potential future directions in this rapidly evolving field.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"136 ","pages":"Article 102941"},"PeriodicalIF":9.6000,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Current and future directions in theranostics for neuroendocrine prostate cancer\",\"authors\":\"Gokce Belge Bilgin , Fabrice Lucien-Matteoni , Aadel A. Chaudhuri , Jacob J. Orme , Daniel S. Childs , Miguel Muniz , Gary G. Li , Pradeep S. Chauhan , SeungBaek Lee , Sounak Gupta , Matthew P. Thorpe , Derek R. Johnson , Geoffrey B. Johnson , Ayse Tuba Kendi , Oliver Sartor\",\"doi\":\"10.1016/j.ctrv.2025.102941\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Neuroendocrine prostate cancer (NEPC) is rare at the time of initial diagnosis but much more common in patients treated with the combination of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) such as abiraterone and enzalutamide. NEPC is typically characterized by the loss of prostate-specific membrane antigen (PSMA) expression while exhibiting variable neuroendocrine markers. Recent advancements in nuclear medicine have provided a promising avenue for the development of molecular imaging techniques and targeted therapies tailored to NEPC. This review examines the current and future role of theranostics in the diagnosis and management of NEPC and explores potential future directions in this rapidly evolving field.</div></div>\",\"PeriodicalId\":9537,\"journal\":{\"name\":\"Cancer treatment reviews\",\"volume\":\"136 \",\"pages\":\"Article 102941\"},\"PeriodicalIF\":9.6000,\"publicationDate\":\"2025-04-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer treatment reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0305737225000635\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0305737225000635","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

神经内分泌前列腺癌（NEPC）在最初诊断时很罕见，但在联合使用雄激素剥夺疗法（ADT）和雄激素受体途径抑制剂（ARPI）（如阿比特龙和恩杂鲁胺）的患者中更为常见。NEPC的典型特征是前列腺特异性膜抗原（PSMA）表达缺失，同时表现出可变的神经内分泌标志物。核医学的最新进展为开发针对NEPC的分子成像技术和靶向治疗提供了一条有希望的途径。本文综述了目前和未来治疗学在NEPC诊断和管理中的作用，并探讨了这一快速发展领域的潜在未来方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Current and future directions in theranostics for neuroendocrine prostate cancer

Neuroendocrine prostate cancer (NEPC) is rare at the time of initial diagnosis but much more common in patients treated with the combination of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) such as abiraterone and enzalutamide. NEPC is typically characterized by the loss of prostate-specific membrane antigen (PSMA) expression while exhibiting variable neuroendocrine markers. Recent advancements in nuclear medicine have provided a promising avenue for the development of molecular imaging techniques and targeted therapies tailored to NEPC. This review examines the current and future role of theranostics in the diagnosis and management of NEPC and explores potential future directions in this rapidly evolving field.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer treatment reviews 医学-肿瘤学

CiteScore

21.40

自引率

0.80%

发文量

109

审稿时长

13 days

期刊介绍： Cancer Treatment Reviews Journal Overview: International journal focused on developments in cancer treatment research Publishes state-of-the-art, authoritative reviews to keep clinicians and researchers informed Regular Sections in Each Issue: Comments on Controversy Tumor Reviews Anti-tumor Treatments New Drugs Complications of Treatment General and Supportive Care Laboratory/Clinic Interface Submission and Editorial System: Online submission and editorial system for Cancer Treatment Reviews